A Phase 1 interventional study of Enlicitide in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-03.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to learn what happens to enlicitide in a person's body over time when enlicitide is taken at the same time as coffee or tea. Researchers will measure the amount of enlicitide in the blood when taken with coffee or tea compared with enlicitide taken with water.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The key inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be randomized to receive enlicitide administered with water in period 1 and enlicitide with coffee in period 2.
Drug: Enlicitide
Participants will be randomized to receive enlicitide administered with coffee in period 1 and enlicitide with water in period 2.
Drug: Enlicitide
Participants will be randomized to receive enlicitide administered with water in period 1 and enlicitide with tea in period 2.
Drug: Enlicitide
Participants will be randomized to receive enlicitide administered with tea in period 1 and enlicitide with water in period 2.
Drug: Enlicitide
Single dose of enlicitide is administered orally on day 1 of each testing period
Also known as: MK-0616, enlicitide decanoate
Part 1-Coffee: Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Enlicitide
Blood samples will be collected to determine the AUC0-inf of enlicitide when administered with coffee
Time frame: Predose and at designated time points up to 168 hours
Part 1-Coffee: Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-last) of Enlicitide
Blood samples will be collected to determine the AUC from time 0 to the time of last quantifiable sample of enlicitide when administered with coffee
Time frame: Predose and at designated time points up to 168 hours
Part 1 -Coffee : Maximum Plasma Concentration (Cmax) of Enlicitide
Blood samples will be collected to determine the maximum observed drug concentration of enlicitide when administered with coffee
Time frame: Predose and at designated time points up to 168 hours
Part 2 -Tea: AUC0-last of Enlicitide
Blood samples will be collected to determine the AUC from time 0 to the time of last quantifiable sample of enlicitide when administered with tea
Time frame: Predose and at designated time points up to 168 hours
Part 2 - Tea: AUC0-Inf of Enlicitide
Blood samples will be collected to determine the AUC0-inf of enlicitide when administered with tea.
Time frame: Predose and at designated time points up to 168 hours
Part 2 -Tea: Cmax of Enlicitide
Blood samples will be collected to determine the maximum observed drug concentration of enlicitide when administered with tea
Time frame: Predose and at designated time points up to 168 hours
Part 1 - Coffee: Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 7 weeks
Part 2 - Tea: Number of Participants Who Experience an Adverse Event (AE)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 7 weeks
Part 1 - Coffee: Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 7 weeks
Part 2 - Tea: Number of Participants Who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 7 weeks
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Jul 2025 to primary completion in Aug 2025, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enlicitide